We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


CuraGen Subsidiary, 454 Life Sciences, Strengthens Management Team

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "CuraGen Subsidiary, 454 Life Sciences, Strengthens Management Team "

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

CuraGen Corporation has announced Mary L. Schramke, Ph.D., MBA, has joined 454 Life Sciences as Vice President of Marketing.

Dr. Schramke will be responsible for 454 Life Sciences' overall marketing activities including further developing 454 Life Sciences' brand identity, expanding the 454 product portfolio, and managing the strategic distribution partnership with Roche Applied Sciences.

"We are delighted to welcome Mary Schramke to 454 Life Sciences," commented Christopher K. McLeod, President and CEO of 454 Life Sciences Corporation.

"Mary's scientific background and wealth of experience in life sciences product development and marketing makes her ideally suited to lead 454 Life Sciences' marketing and commercialization efforts."

Dr. Frank Armstrong, President and CEO of CuraGen Corporation added, "I am delighted that Mary has joined 454 Life Sciences, and we are confident that her addition to the team will drive value creation for the shareholders of both CuraGen and 454 Life Sciences."

Dr. Schramke joins the company from Solexa, Inc. (formerly Lynx Therapeutics, Inc.). Most recently, she was Vice President and General Manager, Genomic Services.

Dr. Schramke served as Acting CEO of Lynx from December 2004 through March 2005, responsible for completion of the merger transaction between Lynx and Solexa, Ltd., UK.

Prior to that she was Vice President of Product Development at Lynx where she led technology development and strategic partnerships, with a specific focus on DNA sequencing instrumentation and applications. Dr. Schramke joined Lynx in 2003 as Senior Director of Business Development.

Earlier in her career, Dr. Schramke held positions of increasing responsibility in business development and marketing for life sciences tools and services, informatics, and bio-pharmaceutical companies such as Bio-Rad Laboratories, Clontech Laboratories, Cellomics, Inc., and Hyseq Pharmaceuticals.

Dr. Schramke earned her Ph.D. in microbiology from Louisiana State University at Baton Rouge, and completed her post-doctoral training in plant genetics at the University of Missouri-Columbia. She also holds an MBA from John F. Kennedy University